Comparative proteomics analysis of microvesicles in human serum for the evaluation of osteoporosis
Comparative proteomics analysis of microvesicles in human serum for the evaluation of osteoporosis
复制标题
人血清中微泡的比较蛋白质组学分析用于评估骨质疏松症
DOI：
10.1002/elps.201900130
复制
发表时间：
2019-07-01
期刊：
影响因子：
2.9
通讯作者：
Xiao, Hua
中科院分区：
文献类型：
--
作者：
Huo, Chunhui;Li, Yinghua;Xiao, Hua
骨质疏松症是一个全球性的新兴健康问题。由于骨密度的降低和骨骼微结构的恶化，骨质疏松症可导致骨脆性增加和骨折风险增加。由于缺乏特异性的症状，迫切需要新的血清蛋白质组学指标来评估骨质疏松症。微泡是广泛存在于体液中的重要信使，已成为多种疾病诊断的新靶点。在这项研究中，MV成功地从人血清中分离和全面表征。比较蛋白质组学分析显示正常人、骨质疏松症患者和骨质疏松症患者的MVs蛋白质谱存在差异。从血清MVs中共鉴定并定量了约200种蛋白质，其中19种蛋白质在骨量减少组和骨质疏松组中与正常组相比表达上调（倍数变化>2），5种蛋白质表达下调（倍数变化<0.5）。选择三种蛋白候选物用于初始验证，包括纤维蛋白、细丝蛋白A和Profilin 1。Profilin 1在独立样本集中进一步预验证，可区分骨质疏松组与骨量减少组和正常组（p < 0.05）。我们的数据共同表明，血清MVs蛋白质组可以作为评估和诊断骨丢失疾病的有价值的指标。
Osteoporosis is an emerging health issue worldwide. Due to the decrease of bone mineral density and the deterioration of skeletal microarchitecture, osteoporosis could lead to increased bone fragility and higher fracture risk. Since lack of specific symptoms, novel serum proteomic indicators are urgently needed for the evaluation of osteoporosis. Microvesicles (MVs) are important messengers widely present in body fluids and have emerged as novel targets for the diagnosis of multiple diseases. In this study, MVs were successfully isolated from human serum and comprehensively characterized. Comparative proteomics analysis revealed differential MVs protein profiling in normal subjects, osteopenia patients, and osteoporosis patients. In total, about 200 proteins were identified and quantified from serum MVs, among which 19 proteins were upregulated (fold change >2) and five proteins were downregulated (fold change <0.5) in osteopenia group and osteoporosis group when compared with the normal group. Three protein candidates were selected for initial verification, including Vinculin, Filamin A, and Profilin 1. Profilin 1 was further pre‐validated in an independent sample set, which could differentiate osteoporosis group from osteopenia group and normal group (p < 0.05). Our data collectively demonstrate that serum MVs proteome can be valuable indicators for the evaluation and diagnostics of bone loss disease.